83 related articles for article (PubMed ID: 11990864)
21. Effectiveness of psoriatic arthritis therapies.
Gladman DD
Semin Arthritis Rheum; 2003 Aug; 33(1):29-37. PubMed ID: 12920694
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
Antoni C; Manger B
Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
[TBL] [Abstract][Full Text] [Related]
23. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept.
Moustou AE; Stratigos AJ; Vergou T; Gregoriou S; Georgala S; Danopoulou I
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):968-9. PubMed ID: 19207660
[No Abstract] [Full Text] [Related]
24. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober BE; Clarke S
J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
[TBL] [Abstract][Full Text] [Related]
25. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis.
Anandarajah AP; Schwarz EM; Totterman S; Monu J; Feng CY; Shao T; Haas-Smith SA; Ritchlin CT
Ann Rheum Dis; 2008 Mar; 67(3):296-301. PubMed ID: 17967829
[TBL] [Abstract][Full Text] [Related]
26. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis.
Bliddal H; Terslev L; Qvistgaard E; Konig M; Holm CC; Rogind H; Boesen M; Danneskiold-Samsøe B; Torp-Pedersen S
Scand J Rheumatol; 2006; 35(5):341-5. PubMed ID: 17062431
[TBL] [Abstract][Full Text] [Related]
27. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus.
Mikhail M; Weinberg JM; Smith BL
Arch Dermatol; 2008 Apr; 144(4):453-6. PubMed ID: 18427038
[No Abstract] [Full Text] [Related]
29. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Davis JC; Van Der Heijde D; Braun J; Dougados M; Cush J; Clegg DO; Kivitz A; Fleischmann R; Inman R; Tsuji W;
Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
[TBL] [Abstract][Full Text] [Related]
30. [Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept].
Mrowietz U; Barth J; Boehncke WH; Rosenbach T; Wozel G
J Dtsch Dermatol Ges; 2005 Jun; 3(6):470-2. PubMed ID: 15892851
[No Abstract] [Full Text] [Related]
31. Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary?
Tiliakos AN; Tiliakos NA
J Rheumatol; 2003 Dec; 30(12):2727. PubMed ID: 14719226
[No Abstract] [Full Text] [Related]
32. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
Wallenius M; Rødevand E; Skomsvoll JF
Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1664-6. PubMed ID: 15976836
[TBL] [Abstract][Full Text] [Related]
33. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein.
Zhou H
J Clin Pharmacol; 2005 May; 45(5):490-7. PubMed ID: 15831771
[TBL] [Abstract][Full Text] [Related]
34. Treating leukocytoclastic vasculitis associated with etanercept therapy. Is it necessary to stop etanercept?
Juan A; Ribas B; Nadal C; Ros I
J Rheumatol; 2005 Oct; 32(10):2061; author reply 2061-2. PubMed ID: 16206372
[No Abstract] [Full Text] [Related]
35. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis.
Bathon JM; Fleischmann RM; Van der Heijde D; Tesser JR; Peloso PM; Chon Y; White B
J Rheumatol; 2006 Feb; 33(2):234-43. PubMed ID: 16465653
[TBL] [Abstract][Full Text] [Related]
36. Successful etanercept treatment of constrictive pericarditis complicating rheumatoid arthritis.
Aslangul E; Perrot S; Durand E; Mousseaux E; Le Jeunne C; Capron L
Rheumatology (Oxford); 2005 Dec; 44(12):1581-3. PubMed ID: 16204377
[No Abstract] [Full Text] [Related]
37. Treatment with etanercept for patients with juvenile rheumatoid arthritis in Taiwan--a preliminary report.
Liang TC; Yang YH; Lin YT; Chiang BL
J Microbiol Immunol Infect; 2005 Dec; 38(6):447-50. PubMed ID: 16341347
[TBL] [Abstract][Full Text] [Related]
38. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
Ollendorf DA; Peterson AN; Doyle J; Huse DM
Am J Manag Care; 2002 May; 8(7 Suppl):S203-13. PubMed ID: 12022236
[TBL] [Abstract][Full Text] [Related]
39. Patient preferences for treatment of rheumatoid arthritis.
Fraenkel L; Bogardus ST; Concato J; Felson DT; Wittink DR
Ann Rheum Dis; 2004 Nov; 63(11):1372-8. PubMed ID: 15020312
[TBL] [Abstract][Full Text] [Related]
40. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.
Kremer JM; Weinblatt ME; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Jackson CG; Atkins KM; Feng A; Burge DJ
Arthritis Rheum; 2003 Jun; 48(6):1493-9. PubMed ID: 12794815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]